Description:
A MEK inhibitor that suppresses MEK1 and MEK2 with IC50 of 0.92 and 1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. It has been approved by FDA, in combination with Tafilnar, for the treatment of metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation.
- Molecular Weight: 615.39
- Molecular Formula: C26H23FIN5O4
Purity: ≥98%
Canonical SMILES:
CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
InChI:
InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
InChIKey: LIRYPHYGHXZJBZ-UHFFFAOYSA-N
- Melting Point: 299-301 °C
- Appearance: Off-White Solid
Synonyms:
GSK-1120212; GSK 1120212; GSK1120212; JTP74057; JTP 74057; JTP-74057; Mekinist
More details are to be found on supplier website
